Although the predominant translocations in MM do not fully explain the pathogenesis of the malignant plasma cell, the identification of genetic entities has facilitated the development of targeted therapy, such as FGFR3-kinase inhibitors in t(4;14) MM [2]. The gene discussed is FGFR3; the disease is Miyoshi myopathy.